Human Donor Milk Safety, A Nurse Leadership Call to Action - Recording
Human donor milk and human donor-milk products have become increasingly critical “medical” therapies for premature NICU babies weighing 1,250 grams or less at birth. Conclusive data and lived experience as NICU Nurse Leaders affirms the clinical benefits of human milk, most especially in this fragile cohort.
Due to the clinical success of human donor milk and human donor-milk products, there has been an enormous growth in the human milk industry over the last six years. While this is potentially great news for fragile preemies with more human milk available, it also elevates risk as more and more companies and milk banks enter the market in a completely unregulated environment (human milk is currently regulated as a food). Considering that human milk, as a biologic, has the inherent risk of transmitting pathogens, adulterants, nicotine, and many other substances, we find ourselves in a time of considering safer methods.
In this webinar, we will look at all the risks secondary to the industry’s growth. Together we’ll evaluate what is currently being done to mitigate these risks, and what strategies we can put in place to advocate together to protect these tiny patients moving forward.
- Understand the clinical rationale behind the growth of the human milk industry for very low birthweight premature infants
- Examine the current methods of donor screening, milk testing and pasteurization
- Explore ways to advocate for uniform standards and regulation to protect our most vulnerable patients
NOTE: No CEs and CMEs are not available for the recorded version of this presentation.
Disclosure: Dr. Goldstein has no direct financial relationship with Prolacta.
Mitchell Goldstein, MD
Professor of Pediatrics
Loma Linda University
Dr. Goldstein attended the University of Miami’s Honor Program in Medical Education, completed his pediatric residency at the University of California, Los Angeles, and finished his Neonatal-Perinatal Medicine fellowship at the University of California, Irvine. Dr. Goldstein is board certified in both Pediatrics and Neonatal-Perinatal Medicine. He is a Professor of Pediatrics at Loma Linda University Children’s Hospital.
Dr. Goldstein’s most important trait is his tireless devotion to patient access issues. When his hospital and many others nationwide could not purchase equipment vital to patient care, Dr. Goldstein rallied. He wrote senators and congressman. He testified in front of a United States Senate Sub-Committee of the Judiciary regarding the practices of the Group Purchasing Organizations and the potential for restriction of access to vital medical devices. The story of Dr. Goldstein’s vigilance, success in helping modify these practices, and improve patient care made the front page of the New York Times. Dr. Goldstein has been a vocal advocate for “right” sizing technology.
He is a past president of the National Perinatal Association (NPA) and author of the NPA’s Respiratory Syncytial Virus (RSV) Prophylaxis 2018 Guidelines. Additionally, Dr. Goldstein is editor in chief of Neonatology Today. Dr. Goldstein is the Medical Director of the National Coalition for Infant Health. In this role, he lobbies for access to critical medical therapies and technology development including those essential to the prevention of NEC. He is also the outgoing chair National Chair of the Section on Advances in Therapeutics & Technology (SOATT) of the American Academy of Pediatrics.
Dr. Goldstein advocates for improvement in in the physician-patient relationship as a crucial in providing exceptional care for our patients. He is a firm believer in physician leadership as a vital part of the pathyway to high quality patient care. He is vocal advocate on payment models that will sustain and support both academic and community physician practices. Adequate remuneration is key to access to care. Dr. Goldstein continues promote improvement of the medical profession through education, research, and treatment models.